Hosted on MSN7d
J&J’s Spravato receives FDA label expansion for depression monotherapy
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...
Hosted on MSN7d
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...
BioSpace7d
J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
pharmaphorum7d
J&J's Spravato gets another lift with new FDA approval
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...
Pharm Exec8d
FDA Approves Johnson & Johnson’s Spravato for Treatment-Resistant Depression
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
J&J's Spravato Wins FDA Approval, Stands as a Game-Changer for Mental Health Care
New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
NJBIZ7d
J&J’s ketamine-based drug approved as standalone treatment
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Ketamine-Derived Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
BioSpace16h
Atai Touts Positive Data for Psychedelic Therapy in Alcohol Use Disorder
The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...
Yahoo Finance7d
J&J’s Spravato receives FDA label expansion for depression monotherapy
Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy treatment for major depressive disorder (MDD) in adults who do not ...